
    
      HGT-REP-060 was designed to provide participants who participated in TKT028 an additional 52
      weeks of treatment with Replagal at the standard dose of 0.2 milligram per kilogram (mg/kg)
      every other week (EOW) to assess the effect of continued Replagal therapy on long-term safety
      and clinical outcomes for this participant population.
    
  